Ladenburg, Germany, 21 June 2024 – Heidelberg Pharma AG (FSE: HPHA) announced that the company's shareholders approved the following proposed resolutions of the management with a large majority (between 98,35% and 99,99%) at yesterday’s ordinary virtual Annual General Meeting:
- Discharge of the members of the Management Board and the Supervisory Board for the fiscal year 2022/2023
- Appointment of the auditors and group auditors for fiscal year 2023/2024
- Cancellation of Authorised Capital 2022/I and creation of new Authorised Capital 2024/I with the option to exclude statutory subscription rights and corresponding amendments to the Articles of Association
- Approval of the remuneration report
Attendance (incl. postal votes cast) at the Annual General Meeting 2024 corresponded to 83,18% of the current capital stock.
For more information on the Annual General Meeting, including the voting results, please visit: https://heidelberg-pharma.com/de/hv
